This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

North America Injectable Drug Delivery Market - By Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] - Forecasts To 2017

NEW YORK, April 10, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: North America Injectable Drug Delivery Market – by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] – Forecasts to 2017

http://www.reportlinker.com/p01158258/North-America-Injectable-Drug-Delivery-Market-–-by-Formulations-[Liposomes-Microspheres--Nanoparticles]-Devices-[Disposables--Reusable-Fillable--Prefilled-Pen-Needle-Free--Auto-Injectors]--Therapeutics-[Diabetes--Oncology]-–-Forecasts-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

The North American injectable drug delivery technologies market was valued at $9.3 billion in 2012; it is expected to reach $16.6 billion by 2017 at a CAGR of 12.3% from 2012 to 2017. Injectable drug delivery technologies are the combination of two major segments; devices and formulations. The North American injectable drug delivery formulations technologies market was the largest segment in this market. In addition, the market is segmented on the basis of its therapeutic applications. In therapeutic area, hormonal disorders command the major segment of injectable drug delivery technologies market due to high demand of injectable in treatment of diabetes. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self injection devices.The major markets covered in this report are United States and Canada. The United States accounted for the largest market of the North American injectable drug delivery technologies market in the year 2012. However, Canada is expected to witness high growth due to growing prevalence of diabetes and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis, increase in approval of injectable formulation and device, favorable reimbursement and rise in injectable cosmetic treatments.The growth of the injectable drug delivery technologies market is driven by factors such as innovations in injectable drug delivery devices, rising prevalence of diabetes in the U.S. and Canada, improving patient compliance and rise in partnerships, collaborations and acquisitions among prominent players in this market. However, factors such as product recalls, regulatory hurdles for approval of new device sand formulations and needle-stick injuries and infections, are restraining the growth of the market.

Scope of the ReportThis research report categorizes and analyzes the North American injectable drug delivery technologies market under two broad segments - devices and formulations. Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Furthermore, due to wide range of applications of injectable drug delivery technologies in varied therapeutic areas, the market is segmented into five categories, namely; auto immune diseases, hormonal imbalances, oncology, orphan/rare diseases (Hemophilia, Ribose-5-phosphate isomerase deficiency (RPI deficiency), Cystic Fibrosis, Wilson's Disease) and others (pain management, allergies, hepatitis C, and aesthetic treatment). Each market is comprehensively analyzed at a granular level by country ( United States and Canada) to provide in-depth information on the North American scenario. Injectable Drug Delivery Technologies Market, By SegmentInjectable Drug Delivery Devices TechnologiesInjectable Drug Delivery Formulations Technologies Injectable Drug Delivery Devices Technologies Market, By ProductConventional Injection DevicesBy MaterialsGlassPlasticsBy ProductFillable SyringesPrefilled SyringesBy UsabilityReusableDisposableSelf-Injection DevicesNeedle Free InjectorsBy ProductFillable SyringesPrefilled SyringesBy TechnologyJet-based Needle Free InjectorsSpring-based Needle Free InjectorsLaser Powered Needle Free InjectorsOthersBy UsabilityReusableDisposableAuto InjectorsBy ProductFillable SyringesPrefilled SyringesBy TechnologyManual Injection Auto InjectorsAutomated Injection Auto InjectorsBy DesignStandardized Auto InjectorsCustomized Auto InjectorsBy UsabilityReusableDisposablePen InjectorsBy ProductSingle Chambered Pen InjectorsDual Chambered Pen InjectorsBy designStandardized pen injectorsCustomized pen injectorsBy usabilityReusableDisposableOthers (blunt needle, micro needle, and nano needle injections)

Injectable Drug Delivery Formulations Technologies, By ProductConventional Drug Delivery FormulationSolutionReconstituted / Lyophilized FormulationNovel Drug Delivery FormulationLiposomal SystemsMicrospheresNanoparticlesPolymeric MicellesOthers (dendrimers, nanosponge, and nanoemulsions) Injectable Drug Delivery Technologies Market, B y Therapeutic ApplicationsAuto Immune DiseasesMultiple SclerosisRheumatoid ArthritisCrohn's DiseasesPsoriasisOthersHormonal DisordersDiabetesAntithrombotic/Thrombolytic TherapyReproductive Health DiseasesAnemiaOsteoporosisOthersOrphan DiseasesOncologyOthersPain ManagementAllergiesHepatitis CAesthetic Treatment

TABLE OF CONTENTS 1 INTRODUCTION 221.1 KEY TAKE-AWAYS 221.2 REPORT DESCRIPTION 221.3 MARKETS COVERED 241.4 STAKEHOLDERS 271.5 RESEARCH METHODOLOGY 271.5.1 MARKET SIZE 271.5.2 MARKET SHARE 281.5.3 KEY DATA POINTS FROM SECONDARY SOURCES 281.5.4 KEY DATA POINTS FROM PRIMARY SOURCES 281.5.5 ASSUMPTIONS 29 2 EXECUTIVE SUMMARY 30 3 MARKET OVERVIEW 353.1 INTRODUCTION 363.2 MARKET SEGMENTATION 403.3 MARKET DYNAMICS 423.4 DRIVERS 433.4.1 INNOVATIONS IN INJECTABLE DRUG DELIVERY DEVICES 433.4.2 SURGE OF BIOLOGICS 443.4.3 RISING PREVALENCE OF DIABETES IN THE U.S.AND CANADA 443.4.4 IMPROVEMENT IN PATIENT COMPLIANCE 453.4.5 INCESSANT RISE IN PARTNERSHIPS, COLLABORATIONS AND ACQUISITIONS 463.5 RESTRAINTS 473.5.1 PRODUCT RECALLS 473.5.2 STRINGENT REGULATORY SYSTEMS 473.5.3 NEEDLE-STICK INJURIES AND INFECTIONS 483.6 OPPORTUNITIES 493.6.1 DEVELOPMENT OF BIOSIMILARS 493.6.2 ADVANCEMENTS IN NANOTECHNOLOGYAND OTHERS 503.7 CHALLENGES 513.7.1 SUSTAINABILITY OF PLAYERS IN HIGHLY COMPETITIVE MARKET 513.8 MARKET SHARE ANALYSIS, BY MAJOR PLAYERS 523.8.1 INJECTABLE DRUG DELIVERY DEVICES 52 4 INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET 564.1 INTRODUCTION 574.2 MARKET SEGMENTATION 604.3 MANUFACTURERS CRITERIA FOR SELECTION OF AN INJECTABLE DEVICE 614.4 CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES 634.4.1 BY USABILITY 654.4.1.1 Disposable 654.4.1.2 Reusable 664.4.2 BY MATERIAL 684.4.2.1 Glass 684.4.2.2 Plastic 704.4.3 BY PRODUCT 714.4.3.1 Prefilled 724.4.3.2 Fillable 744.5 SELF-INJECTION DEVICES 754.5.1 MARKET SEGMENTATION 794.5.2 SELECTION CRITERIA FOR SELF-INJECTION DEVICE 794.5.3 PEN INJECTORS 814.5.3.1 By Product 834.5.3.1.1 Single chamber pen injectors 844.5.3.1.2 Dual chamber pen injectors 864.5.3.2 By Usability 874.5.3.2.1 Disposable pen injectors 884.5.3.2.2 Reusable pen injectors 894.5.3.3 By Design 904.5.3.3.1 Standard pen injectors 914.5.3.3.2 Customized pen injectors 924.5.4 NEEDLE-FREE INJECTORS 934.5.4.1 By Product 954.5.4.1.1 Prefilled needle free injectors 954.5.4.1.2 Fillable needle free injectors 964.5.4.2 By Technology 984.5.4.2.1 Jet-based needle-free injectors 994.5.4.2.2 Spring-based needle-Free injectors 1004.5.4.2.3 Laser-based needle free injectors 1014.5.4.2.4 Vibration-based needle free injectors 1024.5.4.3 By Usability 1044.5.4.3.1 Disposable 1044.5.4.3.2 Reusable 1064.5.5 AUTO INJECTORS 1074.5.5.1 By Product 1094.5.5.1.1 Prefilled auto injectors 1094.5.5.1.2 Fillable auto injectors 1114.5.5.2 By Technology 1124.5.5.2.1 Automated auto injectors 1124.5.5.2.2 Manual auto injectors 1134.5.5.3 By Design 1154.5.5.3.1 Standardized auto injectors 1154.5.5.3.2 Customized auto injectors 1174.5.5.4 By Usability 1184.5.5.4.1 Disposable auto injectors 1184.5.5.4.2 Reusable auto injectors 1204.6 OTHERS 121 5 INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET 1235.1 INTRODUCTION 1245.2 CONVENTIONAL DRUG DELIVERY 1265.2.1 INJECTABLE SOLUTIONS 1295.2.2 RECONSTITUTED/LYOPHILIZED FORMULATIONS 1315.3 NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES 1335.3.1 MARKET SEGMENTATION 1355.3.2 LIPOSOMAL SYSTEMS 1365.3.3 MICROSPHERES 1385.3.4 NANOPARTICLES 1405.3.5 POLYMERIC MICELLES 1415.3.6 OTHERS 143 6 INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATIONS 1456.1 INTRODUCTION 1466.2 AUTO-IMMUNE DISEASES 1506.2.1 MULTIPLE SCLEROSIS 1526.2.2 RHEUMATOID ARTHRITIS 1546.2.3 CROHN'S DISEASE 1556.2.4 PSORIASIS 1566.2.5 OTHERS 1586.3 HORMONAL DISORDERS 1596.3.1 DIABETES 1616.3.2 ANEMIA 1636.3.3 REPRODUCTIVE HEALTH DISEASES 1646.3.4 ANTITHROMBOTIC/THROMBOLYTIC THERAPY 1666.3.5 OSTEOPOROSIS 1676.3.6 GROWTH HORMONE DEFICIENCY 1696.4 ORPHAN/RARE DISEASES 1716.5 ONCOLOGY 1736.6 OTHERS 1756.6.1 PAIN MANAGEMENT 1766.6.2 HEPATITIS C 1786.6.3 ALLERGIES 1796.6.4 AESTHETIC TREATMENT 181 7 GEOGRAPHIC ANALYSIS 1837.1 INTRODUCTION 1847.1.1 U.S. 1867.1.1.1 Product innovation stimulating the growth of injectable drug delivery devices in U.S. 1877.1.1.2 Incessant rise in number of diseases requiring injectable drug delivery-based treatment in U.S. 1907.1.2 CANADA 1927.1.2.1 Rise in number of approvals of injectable drug delivery devices 1937.1.2.2 Canadian market impacted due to shortage of injectable drugs 1957.1.2.3 Insurance coverage favoring the growth of Canadian injectable drug delivery technology market 197 8 COMPETITIVE LANDSCAPE 1988.1 INTRODUCTION 1988.2 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS &JOINT VENTURES 2028.3 NEW PRODUCT LAUNCH 2078.4 EXPANSION 2118.5 MERGERS & ACQUISITIONS 2148.6 OTHER DEVELOPMENTS 2168.7 APPROVALS 218 9 COMPANY PROFILES 2209.1 ANTARES PHARMA, INC. 2209.2 BAXTER INTERNATIONAL, INC. 2279.3 BECTON, DICKINSON AND COMPANY 2339.4 ELI LILLY AND COMPANY 2409.5 HOSPIRA, INC. 2469.6 NOVO NORDISK A/S 2549.7 SANOFI 2619.8 UNILIFE CORPORATION 2669.9 WEST PHARMACEUTICAL SERVICES, INC. 2719.10 ZOGENIX, INC. 276

LIST OF TABLESTABLE 1 NORTH AMERICA: INJECTION DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($MILLION) 32TABLE 2 NORTH AMERICA: INJECTION DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($MILLION) 37TABLE 3 NORTH AMERICA: INJECTION DRUG DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 39TABLE 4 NORTH AMERICA: INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, BY PRODUCT, 2010 – 2017 ($MILLION) 58TABLE 5 NORTH AMERICA: INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 59TABLE 6 NORTH AMERICA: CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 63TABLE 7 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET,BY USABILITY, 2010 – 2017 ($MILLION) 65TABLE 8 DISPOSABLE CONVENTIONAL DEVICES MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 66TABLE 9 REUSABLE CONVENTIONAL DEVICES MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 67TABLE 10 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET,BY MATERIAL, 2010 – 2017 ($MILLION) 68TABLE 11 CONVENTIONAL INJECTION DEVICES (GLASS) MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 69TABLE 12 CONVENTIONAL INJECTION DEVICES (PLASTIC) MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 70TABLE 13 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET,BY PRODUCT, 2010 – 2017 ($MILLION) 72TABLE 14 NORTH AMERICA: PREFILLED CONVENTIONAL INJECTION DEVICES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 73TABLE 15 NORTH AMERICA: FILLABLE CONVENTIONAL INJECTION DEVICES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 74TABLE 16 NORTH AMERICA: SELF-INJECTION DEVICES MARKET, BY PRODUCT, 2010 – 2017 ($MILLION) 76TABLE 17 NORTH AMERICA: SELF-INJECTION DEVICES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 78TABLE 18 NORTH AMERICA: PEN INJECTOR MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 83TABLE 19 NORTH AMERICA: PEN INJECTORS MARKET, BY PRODUCT,2010 – 2017 ($MILLION) 84TABLE 20 NORTH AMERICA: SINGLE CHAMBER PEN INJECTOR MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 85TABLE 21 NORTH AMERICA: DUAL CHAMBER PEN INJECTOR MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 86TABLE 22 NORTH AMERICA: PEN INJECTORS MARKET, BY USABILITY,2010 – 2017 ($MILLION) 87TABLE 23 NORTH AMERICA: DISPOSABLE PEN INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 88TABLE 24 NORTH AMERICA: REUSABLE PEN INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 89TABLE 25 NORTH AMERICA: PEN INJECTORS MARKET, BY DESIGN,2010 – 2017 ($MILLION) 90TABLE 26 NORTH AMERICA: STANDARD PEN INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 91TABLE 27 NORTH AMERICA: CUSTOMIZED PEN INJECTORS MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 92TABLE 28 NORTH AMERICA: NEEDLE FREE INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 94TABLE 29 NORTH AMERICA: NEEDLE FREE INJECTORS MARKET, BY PRODUCT, 2010 – 2017 ($MILLION) 95TABLE 30 NORTH AMERICA: PREFILLED NEEDLE FREE INJECTORS MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 96TABLE 31 NORTH AMERICA: FILLABLE NEEDLE FREE INJECTORS MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 97TABLE 32 NORTH AMERICA: NEEDLE FREE INJECTORS MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION) 98TABLE 33 NORTH AMERICA: JET-BASED NEEDLE FREE INJECTOR MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 99TABLE 34 NORTH AMERICA: SPRING-BASED NEEDLE FREE INJECTOR MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 100TABLE 35 NORTH AMERICA: LASER-POWERED NEEDLE FREE INJECTOR MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 101TABLE 36 NORTH AMERICA: VIBRATION-BASED NEEDLE FREE INJECTOR MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 103TABLE 37 NORTH AMERICA: NEEDLE FREE INJECTORS MARKET, BY USABILITY, 2010 – 2017 ($MILLION) 104TABLE 38 NORTH AMERICA: DISPOSABLE NEEDLE FREE INJECTORS MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 105TABLE 39 NORTH AMERICA: REUSABLE NEEDLE FREE INJECTORS MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 106TABLE 40 NORTH AMERICA: AUTO INJECTORS PRODUCTS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 108TABLE 41 NORTH AMERICA: AUTO INJECTORS MARKET, BY PRODUCT,2010 – 2017 ($MILLION) 109TABLE 42 NORTH AMERICA: PREFILLED AUTO INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 110TABLE 43 NORTH AMERICA: FILLABLE AUTO INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 111TABLE 44 NORTH AMERICA: AUTO INJECTORS MARKET, BY TECHNOLOGY,2010 – 2017 ($MILLION) 112TABLE 45 NORTH AMERICA: AUTOMATED AUTO INJECTORS MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 113TABLE 46 NORTH AMERICA: MANUAL AUTO INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 114TABLE 47 NORTH AMERICA: AUTO INJECTORS MARKET, BY DESIGN,2010 – 2017 ($MILLION) 115TABLE 48 NORTH AMERICA: STANDARDIZED AUTO INJECTORS MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 116TABLE 49 NORTH AMERICA: CUSTOMIZED AUTO INJECTORS MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 117TABLE 50 NORTH AMERICA: AUTO INJECTORS MARKET, BY USABILITY,2010 – 2017 ($MILLION) 118TABLE 51 NORTH AMERICA: DISPOSABLE AUTO INJECTORS MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 119TABLE 52 NORTH AMERICA: REUSABLE AUTO INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 120TABLE 53 NORTH AMERICA: OTHERS INJECTORS MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 121TABLE 54 NORTH AMERICA: INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($MILLION) 124TABLE 55 NORTH AMERICA: INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 125TABLE 56 NORTH AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, 2010 – 2017 ($MILLION) 127TABLE 57 NORTH AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 129TABLE 58 NORTH AMERICA: INJECTABLE SOLUTIONS CONVENTIONAL DRUG DELIVERY FORMULATION MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 130TABLE 59 NORTH AMERICA: RECONSTITUTED/LYOPHILIZED CONVENTIONAL DRUG DELIVERY FORMULATION MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 131TABLE 60 NORTH AMERICA: NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, 2010 – 2017 ($MILLION) 133TABLE 61 NORTH AMERICA: NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 135TABLE 62 NORTH AMERICA: LIPOSOME DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 137TABLE 63 NORTH AMERICA: MICROSPHERES DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 139TABLE 64 NORTH AMERICA: NANOPARTICLES DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 140TABLE 65 NORTH AMERICA: POLYMERIC MICELLES DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 142TABLE 66 NORTH AMERICA: OTHERS NOVEL DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 143TABLE 67 NORTH AMERICAN INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATIONS, 2010 – 2017 ($MILLION) 146TABLE 68 NORTH AMERICA: AUTO IMMUNE THERAPEUTICS MARKET,BY INDICATION, 2010 – 2017 ($MILLION) 151TABLE 69 NORTH AMERICA: AUTO IMMUNE THERAPEUTICS MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 152TABLE 70 NORTH AMERICA: MULTIPLE SCLEROSIS MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 153TABLE 71 NORTH AMERICA: RHEUMATOID ARTHRITIS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 154TABLE 72 NORTH AMERICA: CROHN'S DISEASE MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 156TABLE 73 PSORIASIS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 157TABLE 74 NORTH AMERICA: OTHER AUTO IMMUNE DISEASE MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 158TABLE 75 NORTH AMERICA: HORMONAL DISORDERS MARKET, BY INDICATION, 2010 – 2017 ($MILLION) 160TABLE 76 NORTH AMERICA: HORMONAL DISORDERS MARKET, BY COUNTRY, 2010 – 2017($MILLION) 161TABLE 77 NORTH AMERICA: DIABETES MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 162TABLE 78 NORTH AMERICA: ANEMIA MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 163TABLE 79 NORTH AMERICA: REPRODUCTIVE HEALTH DISEASE MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 165TABLE 80 NORTH AMERICA: ANTITHROMBOTIC THERAPY MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 166TABLE 81 NORTH AMERICA: OSTEOPOROSIS MARKET, BY COUNTRY,2010 – 2017($MILLION) 168TABLE 82 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 169TABLE 83 NORTH AMERICA: ORPHAN/RARE DISEASE MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 171TABLE 84 NORTH AMERICA: ONCOLOGY MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 173TABLE 85 NORTH AMERICA: OTHER THERAPEUTIC MARKET, BY INDICATION, 2010 – 2017 ($MILLION) 175TABLE 86 NORTH AMERICA: OTHER THERAPEUTIC MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 176TABLE 87 NORTH AMERICA: PAIN MANAGEMENT MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 177TABLE 88 NORTH AMERICA: HEPATITIS C MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 178TABLE 89 NORTH AMERICA: ALLERGIES/ANAPHYLYTIC SHOCK MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 180TABLE 90 NORTH AMERICA: AESTHETIC TREATMENT MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 181TABLE 91 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 184TABLE 92 UNITED STATES: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($MILLION) 186TABLE 93 UNITED STATES: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2010 – 2017 ($MILLION) 187TABLE 94 UNITED STATES: INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY PRODUCT, 2010 – 2017($MILLION) 188TABLE 95 UNITED STATES: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATION, 2010 – 2017 ($MILLION) 190TABLE 96 CANADA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET,BY TYPE, 2010 – 2017 ($MILLION) 192TABLE 97 CANADA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET,BY PRODUCT, 2010 – 2017 ($MILLION) 193TABLE 98 CANADA: INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($MILLION) 194TABLE 99 CANADA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET,BY THERAPEUTIC APPLICATION, 2010 – 2017 ($MILLION) 196TABLE 100 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES, 2010 – 2013 202TABLE 101 NEW PRODUCT LAUNCH, 2010 – 2013 207TABLE 102 EXPANSION, 2010 – 2012 211TABLE 103 MERGERS & ACQUISITIONS, 2010 – 2013 214TABLE 104 OTHERS, 2010 – 2013 216TABLE 105 APPROVALS, 2010 – 2013 218TABLE 106 ANTARES PHARMA: TOTAL REVENUES AND R&D EXPENDITURE,2010 – 2012 ($MILLION) 221TABLE 107 ANTARES PHARMA: TOTAL REVENUE, BY PRODUCT,2010 – 2012 ($MILLION) 221TABLE 108 ANTARES PHARMA: TOTAL REVENUE, BY GEOGRAPHY,2010 – 2012 ($MILLION) 222TABLE 109 BAXTER INTERNATIONAL: TOTAL REVENUE AND R&D EXPENSES,2010 – 2012 ($MILLION) 228TABLE 110 BAXTER INTERNATIONAL: TOTAL REVENUE, BY SEGMENT,2010 – 2012 ($MILLION) 228TABLE 111 BAXTER INTERNATIONAL: MEDICAL PRODUCTS TOTAL REVENUE,2010 – 2012($MILLION) 229TABLE 112 BAXTER INTERNATIONAL: TOTAL REVENUE, BY GEOGRAPHY,2010 – 2012 ($MILLION) 230TABLE 113 BECTON DICKINSON: TOTAL REVENUE AND R&D EXPENDITURE,2010 – 2012 ($MILLION) 234TABLE 114 BECTON DICKINSON: TOTAL REVENUE, BY SEGMENT,2010 – 2012 ($MILLION) 234TABLE 115 BECTON DICKINSON: MEDICAL DIVISION TOTAL REVENUE,2010 – 2012 ($MILLION) 235TABLE 116 BECTON DICKINSON: TOTAL REVENUE, BY GEOGRAPHY,2010– 2012 ($MILLION) 235TABLE 117 ELI LILLY & CO: TOTAL REVENUE AND R&D EXPENSES,2010 – 2012 ($BILLION) 241TABLE 118 ELI LILLY & CO: TOTAL REVENUE, BY SEGMENT,2010 – 2012 ($BILLION) 241TABLE 119 ELI LILLY & CO: TOTAL REVENUE BY GEOGRAPHY,2010 – 2012 ($BILLION) 242TABLE 120 HOSPIRA, INC.: TOTAL REVENUE AND R&D EXPENDITURE,2009 – 2011 ($MILLION) 247TABLE 121 HOSPIRA, INC.: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 ($MILLION) 247TABLE 122 HOSPIRA, INC.: TOTAL REVENUE, BY SEGMENT,2009 – 2011($MILLION) 248TABLE 123 NOVO NORDISK: TOTAL REVENUE AND R&D EXPENSES,2010 – 2012 ($BILLION) 255TABLE 124 NOVO NORDISK: TOTAL REVENUE, BY SEGMENT,2010 – 2012($BILLION) 255TABLE 125 NOVO NORDISK: TOTAL REVENUE, BY GEOGRAPHY,2010 – 2012 ($BILLION) 256TABLE 126 SANOFI: TOTAL REVENUE & R&D EXPENDITURE,2009 – 2012 ($BILLION) 262TABLE 127 SANOFI: TOTAL REVENUE, BY SEGMENT, 2009 – 2012 ($BILLION) 262TABLE 128 SANOFI: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2012 ($BILLION) 263TABLE 129 UNILIFE CORPORATION: TOTAL REVENUE AND EXPENDITURE,2009 – 2011 ($MILLION) 267TABLE 130 UNILIFE CORPORATION: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 ($MILLION) 267TABLE 131 WEST PHARMA: TOTAL REVENUES AND R&D EXPENSES,2009 – 2012 ($MILLION) 272TABLE 132 WEST PHARMA: TOTAL REVENUE, BY SEGMENT,2009 – 2012 ($MILLION) 272TABLE 133 WEST PHARMA: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2012 ($MILLION) 273TABLE 134 ZOGENIX, INC.: TOTAL REVENUE AND R&D EXPENDITURE,2010 – 2012 ($MILLION) 277

LIST OF FIGURESFIGURE 1 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET 31FIGURE 2 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY COUNTRY 33FIGURE 3 INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION 36FIGURE 4 MARKET SEGMENTATION OF INJECTABLE DRUG DELIVERY TECHNOLOGIES 40FIGURE 5 MARKET SEGMENTATION OF INJECTABLE DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATION 41FIGURE 6 INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET DYNAMICS 42FIGURE 7 NORTH AMERICA: INJECTABLE DRUG DELIVERY DEVICES MARKET,BY KEY PLAYERS, 2012 52FIGURE 8 INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET SEGMENTATION 60FIGURE 9 FACTORS AFFECTING SELECTION OF AN INJECTABLE DEVICE 61FIGURE 10 NORTH AMERICA: SELF-INJECTION DEVICES MARKET, BY PRODUCT, 2010 & 2017 ($MILLION) 77FIGURE 11 SELF-INJECTION DEVICES MARKET SEGMENTATION 79FIGURE 12 FACTORS AFFECTING SELECTION OF SELF-INJECTION DEVICE 80FIGURE 13 NORTH AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET SEGMENTATION 126FIGURE 14 NORTH AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, 2012 & 2017 128FIGURE 15 NORTH AMERICA: NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET 134FIGURE 16 NORTH AMERICA: NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES SEGMENTATION 136FIGURE 17 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATIONS, 2010 – 2017 ($MILLION) 148FIGURE 18 INJECTABLE DRUG DELIVERY THERAPEUTICS MARKET SEGMENTATION 149FIGURE 19 AUTO-IMMUNE THERAPEUTICS MARKET SEGMENTATION 150FIGURE 20 HORMONAL DISORDERS MARKET SEGMENTATION 159FIGURE 21 KEY GROWTH STRATEGIES, 2010 – 2013 198FIGURE 22 KEY PLAYERS FOCUSING ON AGREEMENTS, PARTNERSHIPS, COLLABORATIONS AND JOINT VENTURES STRATEGY, 2010 – 2013 199FIGURE 23 KEY PLAYERS FOCUSING ON NEW PRODUCT LAUNCH STRATEGY,2010 – 2013 200FIGURE 24 KEY PLAYERS FOCUSING ON EXPANSION, 2010 – 2013 201

To order this report: Drug_Delivery_Technology Industry: North America Injectable Drug Delivery Market – by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] – Forecasts to 2017

Contact Clare: clare@reportlinker.comUS:(339) 368 6001Intl:+1 339 368 6001

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs